At a glance
ClinicalIndex Comparison RecordN/ACompleted· 75 enrolled
Drug / intervention
Xen Matrix ABdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post-Market, Prospective, Multicenter, Single-Arm Trial of XenMatrix™ AB Surgical Graft in All Wound Classes Ventral or Incisional Midline Hernias
In Brief
A clinical study evaluating Xen Matrix AB for Incisional Hernia. Completed, enrolled 75 participants across 11 sites.
Detailed Summary
This study aims to prospectively explore the use of XenMatrix™ AB Surgical Graft for ventral or incisional midline hernia repair in patients across all wound classes ("All Comers") through 24 months post repair.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIncisional Hernia
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMay 2016
Primary CompletionMay 2020
TodayJul 2026
First PostedFeb 25, 2016
Enrollment StartMay 1, 2016
Primary CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 10.4 years ago
Interventions
Xen Matrix ABdevice
Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.